The AMRN story - Value of U.S. Biopharma Patents

The $AMRN/Vascepa story...

A sad 🥲

but insightful🤔

story about the value of U.S. biopharma patents

From ~$23/share to ~$1/share

in ~5 yrs

Vascepa - the "good" fatty acid in fish oil

• Approved for 2 indications

⇨ Pts with very high blood trigs

⇨ Cardiovascular risk reduction

• Existing U.S. patents cover Indication 2 and mfg method

📅 Fall 2018

• Vascepa Reduce-It Ph3 cardiovascular risk results

• Landmark cardiovascular risk Study

⇨ https://lnkd.in/g4AJ4fhK

$$$$AMRN ~$23/share

📅 2020/21

• U.S. Composition patents killed

• Vascepa goes generic in U.S.

• Vascepa approved in EP

⇨ + EP exclusivity & EP comp patents

$$AMRN ~$4.50/share

📅 Q1 2023 Vascepa European sales

• $0.8M

📅 7/28/23

~$140M = Enterprise Value

$AMRN 1.19/share

Lots more patent yada yada

to the AMRN story

Could be called the AMRN patent trap

• Method patent protection

For lead indication

but...

• No composition patent protection

• No FDA exclusivity

• An approved, but unpatented indication

• Generics with "skinny" labels

• Induced vs. direct infringement

Maybe I'll provide a detailed article later🤔

In the meantime...

If you want to read more about the AMRN story

from an investor perspective:

Check out my and BiopharmIQ's AMRN tweet string:

https://lnkd.in/gzgk8rx2

---

About DHL

Double Helix Law (DHL) has decades of experience building strong patent portfolios for life science companies. Learn more about DHL and meet the team.

Want to stay updated on life science patent law? Subscribe to get notified of updates

---

The content on this website (including all pages, articles, and comments) is not legal advice, and does not and is not intended to form or constitute any attorney-client relationship. The content is not a solicitation for business; it is for educational and entertainment purposes only, and reflects the personal views of the author(s) only and not those of any past, present, or future client of DHL. Any content should be double-checked for accuracy and current applicability, and liability is disclaimed for any error or omission.

07/30/23 Published (EJV)